FDA greenlights Vera Therapeutics' Trutakna for IgA nephropathy

The FDA has approved a new therapy from Vera Therapeutics aimed at treating IgA nephropathy, a chronic autoimmune kidney disorder.

The drug, called Trutakna, is intended for patients with this condition, which is marked by immune complex deposits that can progressively impair kidney function and may lead to dialysis.

Vera's chief executive expressed enthusiasm about making the treatment available, noting its importance for patients with few options.

The approval expands the pipeline of therapies targeting immune-mediated kidney diseases and represents a significant milestone for the biotech company.